Lifecore Biomedical, Inc. (LFCR)
USD 6.17
(6.01%)
USD 6.17
(6.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 41.85 Million USD | 53.34% |
| 2023 | 27.29 Million USD | -46.01% |
| 2022 | 50.55 Million USD | -37.95% |
| 2021 | 81.47 Million USD | 8.65% |
| 2020 | 74.98 Million USD | -7.43% |
| 2019 | 81 Million USD | 3.4% |
| 2018 | 78.33 Million USD | -5.83% |
| 2017 | 83.18 Million USD | 17.23% |
| 2016 | 70.95 Million USD | 8.49% |
| 2015 | 65.4 Million USD | 4.54% |
| 2014 | 62.56 Million USD | -0.31% |
| 2013 | 62.76 Million USD | 20.37% |
| 2012 | 52.13 Million USD | 11.66% |
| 2011 | 46.69 Million USD | 38.29% |
| 2010 | 33.76 Million USD | -1.5% |
| 2009 | 34.28 Million USD | -10.33% |
| 2008 | 38.22 Million USD | 18.04% |
| 2007 | 32.38 Million USD | -19.12% |
| 2006 | 40.04 Million USD | 25.25% |
| 2005 | 31.97 Million USD | 7.32% |
| 2004 | 29.79 Million USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 31.34 Million USD | 13.6% |
| 2001 | 27.58 Million USD | -30.03% |
| 2000 | 39.42 Million USD | 144.89% |
| 1999 | 16.1 Million USD | 5.23% |
| 1998 | 15.3 Million USD | 247.73% |
| 1997 | 4.4 Million USD | 120.0% |
| 1996 | 2 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 9.95 Million USD | 264.99% |
| 2024 Q1 | 2.72 Million USD | -67.49% |
| 2024 Q3 | 11.89 Million USD | 19.45% |
| 2024 FY | 41.85 Million USD | 53.34% |
| 2024 Q4 | 17.27 Million USD | 45.22% |
| 2023 Q1 | 6.25 Million USD | -45.67% |
| 2023 Q2 | 7.1 Million USD | 13.69% |
| 2023 Q4 | 8.39 Million USD | 40.36% |
| 2023 FY | 27.29 Million USD | -46.01% |
| 2023 Q3 | 5.97 Million USD | -15.9% |
| 2022 Q3 | 13.89 Million USD | 6.95% |
| 2022 Q1 | 17.51 Million USD | -29.36% |
| 2022 Q2 | 12.99 Million USD | -25.84% |
| 2022 Q4 | 11.5 Million USD | -17.18% |
| 2022 FY | 50.55 Million USD | -37.95% |
| 2021 Q4 | 24.8 Million USD | 25.96% |
| 2021 FY | 81.47 Million USD | 8.65% |
| 2021 Q3 | 19.68 Million USD | -4.59% |
| 2021 Q1 | 16.34 Million USD | -32.14% |
| 2021 Q2 | 20.63 Million USD | 26.24% |
| 2020 Q1 | 15.33 Million USD | -41.49% |
| 2020 FY | 74.98 Million USD | -7.43% |
| 2020 Q2 | 15.51 Million USD | 1.16% |
| 2020 Q3 | 20.04 Million USD | 29.22% |
| 2020 Q4 | 24.09 Million USD | 20.17% |
| 2019 Q3 | 21.21 Million USD | 27.87% |
| 2019 FY | 81 Million USD | 3.4% |
| 2019 Q4 | 26.21 Million USD | 23.54% |
| 2019 Q1 | 16.33 Million USD | -34.15% |
| 2019 Q2 | 16.59 Million USD | 1.57% |
| 2018 Q4 | 24.8 Million USD | 23.26% |
| 2018 Q3 | 20.12 Million USD | 27.78% |
| 2018 Q2 | 15.75 Million USD | -18.32% |
| 2018 Q1 | 19.28 Million USD | -1.89% |
| 2018 FY | 78.33 Million USD | -5.83% |
| 2017 Q1 | 21.14 Million USD | -7.2% |
| 2017 FY | 83.18 Million USD | 17.23% |
| 2017 Q4 | 19.65 Million USD | -16.11% |
| 2017 Q3 | 23.43 Million USD | 23.63% |
| 2017 Q2 | 18.95 Million USD | -10.36% |
| 2016 FY | 70.95 Million USD | 8.49% |
| 2016 Q3 | 12.93 Million USD | -25.1% |
| 2016 Q4 | 22.78 Million USD | 76.2% |
| 2016 Q1 | 17.97 Million USD | -3.71% |
| 2016 Q2 | 17.26 Million USD | -3.96% |
| 2015 Q3 | 16.88 Million USD | 7.78% |
| 2015 Q4 | 18.66 Million USD | 10.57% |
| 2015 FY | 65.4 Million USD | 4.54% |
| 2015 Q2 | 15.66 Million USD | 10.42% |
| 2015 Q1 | 14.18 Million USD | -12.11% |
| 2014 Q4 | 16.14 Million USD | -19.91% |
| 2014 Q2 | 13.73 Million USD | 9.59% |
| 2014 Q1 | 12.53 Million USD | -3.82% |
| 2014 FY | 62.56 Million USD | -0.31% |
| 2014 Q3 | 20.15 Million USD | 46.75% |
| 2013 Q3 | 17.5 Million USD | -5.15% |
| 2013 Q1 | 13.76 Million USD | -6.41% |
| 2013 Q4 | 13.03 Million USD | -25.58% |
| 2013 Q2 | 18.45 Million USD | 34.12% |
| 2013 FY | 62.76 Million USD | 20.37% |
| 2012 Q2 | 13.01 Million USD | 15.64% |
| 2012 Q4 | 14.7 Million USD | 11.65% |
| 2012 FY | 52.13 Million USD | 11.66% |
| 2012 Q1 | 11.25 Million USD | 6.69% |
| 2012 Q3 | 13.17 Million USD | 1.25% |
| 2011 FY | 46.69 Million USD | 38.29% |
| 2011 Q2 | 11.85 Million USD | 0.32% |
| 2011 Q3 | 12.47 Million USD | 5.26% |
| 2011 Q4 | 10.54 Million USD | -15.49% |
| 2011 Q1 | 11.81 Million USD | 26.36% |
| 2010 FY | 33.76 Million USD | -1.5% |
| 2010 Q3 | 8.12 Million USD | 9.57% |
| 2010 Q1 | 8.87 Million USD | -1.54% |
| 2010 Q2 | 7.41 Million USD | -16.38% |
| 2010 Q4 | 9.35 Million USD | 15.07% |
| 2009 Q2 | 7.55 Million USD | -25.35% |
| 2009 FY | 34.28 Million USD | -10.33% |
| 2009 Q4 | 9 Million USD | 18.68% |
| 2009 Q1 | 10.12 Million USD | 4.89% |
| 2009 Q3 | 7.59 Million USD | 0.45% |
| 2008 Q2 | 8.85 Million USD | -1.3% |
| 2008 FY | 38.22 Million USD | 18.04% |
| 2008 Q4 | 9.65 Million USD | -10.2% |
| 2008 Q3 | 10.74 Million USD | 21.34% |
| 2008 Q1 | 8.97 Million USD | -5.17% |
| 2007 FY | 32.38 Million USD | -19.12% |
| 2007 Q4 | 9.46 Million USD | 4.1% |
| 2007 Q3 | 9.09 Million USD | 9.84% |
| 2007 Q2 | 8.27 Million USD | 48.96% |
| 2007 Q1 | 5.55 Million USD | -62.83% |
| 2006 Q1 | 6.59 Million USD | -39.75% |
| 2006 FY | 40.04 Million USD | 25.25% |
| 2006 Q2 | 7.08 Million USD | 7.57% |
| 2006 Q3 | 11.41 Million USD | 61.04% |
| 2006 Q4 | 14.94 Million USD | 30.95% |
| 2005 Q3 | 9.29 Million USD | 55.07% |
| 2005 FY | 31.97 Million USD | 7.32% |
| 2005 Q4 | 10.93 Million USD | 17.64% |
| 2005 Q2 | 5.99 Million USD | 4.46% |
| 2005 Q1 | 5.74 Million USD | -48.9% |
| 2004 Q1 | 6.08 Million USD | -52.25% |
| 2004 Q3 | 7.44 Million USD | 48.07% |
| 2004 Q4 | 11.23 Million USD | 50.81% |
| 2004 FY | 29.79 Million USD | 0.0% |
| 2004 Q2 | 5.03 Million USD | -17.3% |
| 2003 Q2 | 6.33 Million USD | -2.69% |
| 2003 Q3 | 5.72 Million USD | -9.72% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | 12.73 Million USD | 122.58% |
| 2003 Q1 | 6.51 Million USD | -52.8% |
| 2002 Q4 | 13.8 Million USD | 194.43% |
| 2002 Q1 | 7.15 Million USD | -40.39% |
| 2002 Q2 | 2.59 Million USD | -63.72% |
| 2002 Q3 | 4.68 Million USD | 80.48% |
| 2002 FY | 31.34 Million USD | 13.6% |
| 2001 Q4 | 12 Million USD | 106.2% |
| 2001 Q3 | 5.82 Million USD | -41.88% |
| 2001 Q2 | 10.02 Million USD | -0.35% |
| 2001 Q1 | 10.05 Million USD | -27.59% |
| 2001 FY | 27.58 Million USD | -30.03% |
| 2000 FY | 39.42 Million USD | 144.89% |
| 2000 Q2 | 2.2 Million USD | -12.0% |
| 2000 Q4 | 13.88 Million USD | 152.49% |
| 2000 Q3 | 5.5 Million USD | 150.0% |
| 2000 Q1 | 2.5 Million USD | -70.93% |
| 1999 Q1 | 2.6 Million USD | -65.79% |
| 1999 Q2 | 2.6 Million USD | 0.0% |
| 1999 Q3 | 2.8 Million USD | 7.69% |
| 1999 Q4 | 8.6 Million USD | 207.14% |
| 1999 FY | 16.1 Million USD | 5.23% |
| 1998 Q2 | 1.7 Million USD | -10.53% |
| 1998 Q3 | 2.4 Million USD | 41.18% |
| 1998 Q4 | 7.6 Million USD | 216.67% |
| 1998 FY | 15.3 Million USD | 247.73% |
| 1998 Q1 | 1.9 Million USD | 216.67% |
| 1997 FY | 4.4 Million USD | 120.0% |
| 1997 Q2 | 300 Thousand USD | 0.0% |
| 1997 Q3 | 200 Thousand USD | -33.33% |
| 1997 Q4 | 600 Thousand USD | 200.0% |
| 1997 Q1 | 300 Thousand USD | -66.67% |
| 1996 Q3 | 400 Thousand USD | 0.0% |
| 1996 FY | 2 Million USD | 0.0% |
| 1996 Q4 | 900 Thousand USD | 125.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 87.169% |
| Embecta Corp. | 749.9 Million USD | 94.419% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 86.292% |
| Dynavax Technologies Corporation | 182.11 Million USD | 77.02% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 42.724% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 91.465% |
| PainReform Ltd. | -15 Thousand USD | 279100.0% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -40.663% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -401.848% |
| SCYNEXIS, Inc. | 124.51 Million USD | 66.39% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -7454.547% |
| Cosmos Health Inc. | 4.34 Million USD | -862.164% |
| Journey Medical Corporation | 52.52 Million USD | 20.318% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -401.848% |
| Safety Shot Inc | -74.45 Thousand USD | 56306.938% |
| Alpha Teknova, Inc. | 10.29 Million USD | -306.469% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 90.282% |
| Bright Green Corporation | -237.01 Thousand USD | 17757.036% |
| Procaps Group, S.A. | 239.56 Million USD | 82.531% |
| Theratechnologies Inc. | 62.12 Million USD | 32.64% |
| Harrow Health, Inc. | 90.55 Million USD | 53.784% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -781.981% |
| Biofrontera Inc. | 16.62 Million USD | -151.699% |
| DURECT Corporation | 6.83 Million USD | -512.648% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 92.009% |
| Cronos Group Inc. | 6.99 Million USD | -498.636% |
| OptiNose, Inc. | 62.35 Million USD | 32.883% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 90.514% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 13911.881% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -1270.256% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 86.491% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -675.788% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -24.978% |
| Radius Health, Inc. | 307.71 Million USD | 86.4% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -315.266% |
| ProPhase Labs, Inc. | 16.23 Million USD | -157.713% |
| Phibro Animal Health Corporation | 312.48 Million USD | 86.607% |
| Procaps Group S.A. | 239.56 Million USD | 82.531% |
| Alvotech | -69.42 Million USD | 160.283% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -3114.286% |
| Viatris Inc. | 6.43 Billion USD | 99.35% |
| Rockwell Medical, Inc. | 8.7 Million USD | -380.813% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 23.332% |
| SIGA Technologies, Inc. | 122.09 Million USD | 65.723% |
| Tilray Brands, Inc. | 223.35 Million USD | 81.263% |
| Shineco, Inc. | 882.16 Thousand USD | -4643.994% |
| PetIQ, Inc. | 252.74 Million USD | 83.441% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 5713.02% |
| Incannex Healthcare Limited | 12 Thousand USD | -348650.0% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 97.735% |
| Alimera Sciences, Inc. | 61.17 Million USD | 31.584% |
| Silver Spike Investment Corp. | 8.1 Million USD | -416.501% |
| Assertio Holdings, Inc. | 125.04 Million USD | 66.533% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 614547.218% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -898.528% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -538.347% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 1836.388% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -54.331% |
| Hempacco Co., Inc. | -1.21 Million USD | 3542.085% |
| Talphera, Inc. | -4.89 Million USD | 954.954% |
| Alvotech | -69.42 Million USD | 160.283% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 81.121% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 94.102% |
| Currenc Group, Inc. | 17.35 Million USD | -141.123% |
| Kamada Ltd. | 52.59 Million USD | 20.426% |
| Indivior PLC | 907 Million USD | 95.386% |
| Evoke Pharma, Inc. | 4.97 Million USD | -740.572% |
| Flora Growth Corp. | 17.73 Million USD | -135.934% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 1836.388% |
| Evolus, Inc. | 140.52 Million USD | 70.219% |
| HUTCHMED (China) Limited | 453.55 Million USD | 90.773% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 87.833% |
| Akanda Corp. | 111.44 Thousand USD | -37450.808% |